<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:38:11 -0700</creation_date>
  <update_date>2013-01-15 20:38:11 -0700</update_date>
  <accession>HMDBP10806</accession>
  <secondary_accessions>
    <accession>17081</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Dopamine D3 receptor</synonym>
  </synonyms>
  <gene_name>DRD3</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05012</accession>
      <name>Olanzapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14393</accession>
      <name>Cabergoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14413</accession>
      <name>Ropinirole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14535</accession>
      <name>Sulpiride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14553</accession>
      <name>Remoxipride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14557</accession>
      <name>Pramipexole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14727</accession>
      <name>Lisuride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14852</accession>
      <name>Apomorphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15232</accession>
      <name>Pimozide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15315</accession>
      <name>Domperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00181</accession>
      <name>L-Dopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15369</accession>
      <name>Chlorprothixene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15396</accession>
      <name>Paliperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15464</accession>
      <name>Yohimbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15615</accession>
      <name>Rotigotine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15633</accession>
      <name>Amisulpride</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dopamine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:3</chromosome_location>
    <locus>3q13.3</locus>
    <gene_sequence>&gt;1203 bp
ATGGCATCTCTGAGTCAGCTGAGTAGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC
ACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC
CTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG
CAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC
TTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC
ATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT
CTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT
GGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG
GCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC
TGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC
TTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG
AAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA
CAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG
GACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG
AAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA
CTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG
CCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC
TGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG
TCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT
GTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC
TGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>400</residue_number>
    <molecular_weight>44224.3</molecular_weight>
    <theoretical_pi>9.07</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>33-55</region>
      <region>67-92</region>
      <region>105-126</region>
      <region>150-172</region>
      <region>186-209</region>
      <region>330-351</region>
      <region>367-388</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;D(3) dopamine receptor
MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERAL
QTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILN
LCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTV
CSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQ
QTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRK
LSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHV
SPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P35462</uniprot_id>
  <uniprot_name>DRD3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>U32499</genbank_gene_id>
  <genecard_id>DRD3</genecard_id>
  <geneatlas_id>DRD3</geneatlas_id>
  <hgnc_id>HGNC:3024</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Giros B, Martres MP, Sokoloff P, Schwartz JC: [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome] C R Acad Sci III. 1990;311(13):501-8.</reference_text>
      <pubmed_id>2129115</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schmauss C, Haroutunian V, Davis KL, Davidson M: Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8942-6.</reference_text>
      <pubmed_id>8415635</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liu K, Bergson C, Levenson R, Schmauss C: On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain. J Biol Chem. 1994 Nov 18;269(46):29220-6.</reference_text>
      <pubmed_id>7961889</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Villar VA, Jones JE, Armando I, Palmes-Saloma C, Yu P, Pascua AM, Keever L, Arnaldo FB, Wang Z, Luo Y, Felder RA, Jose PA: G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor. J Biol Chem. 2009 Aug 7;284(32):21425-34. Epub 2009 Jun 11.</reference_text>
      <pubmed_id>19520868</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen CH, Liu MY, Wei FC, Koong FJ, Hwu HG, Hsiao KJ: Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene and schizophrenia. Am J Med Genet. 1997 Feb 21;74(1):40-3.</reference_text>
      <pubmed_id>9034004</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lucotte G, Lagarde JP, Funalot B, Sokoloff P: Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families.  Clin Genet. 2006 May;69(5):437-40.</reference_text>
      <pubmed_id>16650084</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, Sokoloff P: A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10753-8. Epub 2006 Jun 29.</reference_text>
      <pubmed_id>16809426</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.</reference_text>
        <pubmed_id>17301410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1.</reference_text>
        <pubmed_id>18992242</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulpiride</name>
        <accession>HMDB14535</accession>
      </metabolite>
      <reference>
        <reference_text>Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7.</reference_text>
        <pubmed_id>19795811</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulpiride</name>
        <accession>HMDB14535</accession>
      </metabolite>
      <reference>
        <reference_text>Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40.</reference_text>
        <pubmed_id>18973551</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remoxipride</name>
        <accession>HMDB14553</accession>
      </metabolite>
      <reference>
        <reference_text>Christian AJ, Goodwin AK, Baker LE: Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001 Mar;68(3):371-7.</reference_text>
        <pubmed_id>11325388</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.</reference_text>
        <pubmed_id>7520908</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J: Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci. 2009 Aug;63(4):529-37. Epub 2009 May 22.</reference_text>
        <pubmed_id>19496999</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. Epub 2008 Sep 20.</reference_text>
        <pubmed_id>18831971</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005 Dec;30(12):2283-9.</reference_text>
        <pubmed_id>16123775</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Malmberg, Mikaels, Mohell N: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. J Pharmacol Exp Ther. 1998 Apr;285(1):119-26.</reference_text>
        <pubmed_id>9536001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisuride</name>
        <accession>HMDB14727</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apomorphine</name>
        <accession>HMDB14852</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimozide</name>
        <accession>HMDB15232</accession>
      </metabolite>
      <reference>
        <reference_text>Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26.</reference_text>
        <pubmed_id>8301582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26.</reference_text>
        <pubmed_id>8301582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Wachtel H: Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect. 1991;3(3):151-201.</reference_text>
        <pubmed_id>1683537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Dopa</name>
        <accession>HMDB00181</accession>
      </metabolite>
      <reference>
        <reference_text>Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease.  Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25.</reference_text>
        <pubmed_id>18549347</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Dopa</name>
        <accession>HMDB00181</accession>
      </metabolite>
      <reference>
        <reference_text>Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.</reference_text>
        <pubmed_id>11978145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Dopa</name>
        <accession>HMDB00181</accession>
      </metabolite>
      <reference>
        <reference_text>Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease.  Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8.</reference_text>
        <pubmed_id>9633680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40.</reference_text>
        <pubmed_id>1830565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.</reference_text>
        <pubmed_id>7520908</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone.  Psychopharmacology (Berl). 1994 Feb;114(1):9-23.</reference_text>
        <pubmed_id>7531353</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A: Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse. 2000 Feb;35(2):79-95.</reference_text>
        <pubmed_id>10611634</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine.  Curr Med Res Opin. 2004 Dec;20(12):1877-81.</reference_text>
        <pubmed_id>15701205</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rotigotine</name>
        <accession>HMDB15615</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amisulpride</name>
        <accession>HMDB15633</accession>
      </metabolite>
      <reference>
        <reference_text>Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13.</reference_text>
        <pubmed_id>12404702</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amisulpride</name>
        <accession>HMDB15633</accession>
      </metabolite>
      <reference>
        <reference_text>Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.</reference_text>
        <pubmed_id>16696579</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amisulpride</name>
        <accession>HMDB15633</accession>
      </metabolite>
      <reference>
        <reference_text>Seeman P: Atypical antipsychotics: mechanism of action.  Can J Psychiatry. 2002 Feb;47(1):27-38.</reference_text>
        <pubmed_id>11873706</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
